INKT (MiNK Therapeutics) Total Liabilities: $23.06 Mil (As of Mar. 2026)


INKT MiNK Therapeutics Inc INKT
34 GF Score
Price $11.75
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics Total Liabilities?

MiNK Therapeutics INKT -0.52% 34 Total Liabilities is $23.06 Mil as of Mar. 2026. GuruFocus rates INKT with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

MiNK Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $23.06 Mil.

MiNK Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($28.48 Mil) to Dec. 2025 ($28.47 Mil) and declined from Dec. 2025 ($28.47 Mil) to Mar. 2026 ($23.06 Mil).

MiNK Therapeutics's annual Total Liabilities increased from Dec. 2023 ($22.61 Mil) to Dec. 2024 ($25.31 Mil) and increased from Dec. 2024 ($25.31 Mil) to Dec. 2025 ($28.47 Mil).

MiNK Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics Total Liabilities Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 16.47 21.87 22.61 25.31 28.47

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.06 27.67 28.48 28.47 23.06
INKT
34GF Score
MiNK Therapeutics Inc INKT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MiNK Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.031+(0+15.436
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=28.47

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=14.239--14.228
=28.47

MiNK Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.287+(0+15.776
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=23.06

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=10.377--12.686
=23.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $23.06 Mil mean?
MiNK Therapeutics (INKT) has a Total Liabilities of $23.06 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MiNK Therapeutics and its competitors.
Is MiNK Therapeutics' Total Liabilities too high?
MiNK Therapeutics' current Total Liabilities is $23.06 Mil. Overall, MiNK Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' Total Liabilities compare to BOLD and FLNA?
MiNK Therapeutics' Total Liabilities of $23.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MiNK Therapeutics and its competitors. MiNK Therapeutics's current Total Liabilities is $23.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current Total Liabilities of $23.06 Mil. The current Total Liabilities is $23.06 Mil. MiNK Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current Total Liabilities is $23.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
34GF Score

Get the complete analysis for INKT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.75
Price